Published in Lancet Oncol on August 14, 2012
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet (2014) 6.36
Progress in molecular-based management of differentiated thyroid cancer. Lancet (2013) 2.44
Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol (2014) 1.67
Current status and future perspectives in differentiated thyroid cancer. Endocrinol Metab (Seoul) (2014) 1.29
The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab (2012) 1.06
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer (2015) 1.05
Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev (2013) 1.02
Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions. Minerva Endocrinol (2012) 1.00
Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab (2014) 0.99
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805. Clin Cancer Res (2015) 0.97
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. Adv Ther (2013) 0.96
New therapies for dedifferentiated papillary thyroid cancer. Int J Mol Sci (2015) 0.94
Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol (2013) 0.92
Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma. Int J Clin Exp Med (2014) 0.92
Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma. Br J Cancer (2013) 0.89
Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. Oncologist (2015) 0.86
Combining molecular targeted agents with radiation therapy for malignant gliomas. Onco Targets Ther (2013) 0.85
Molecular Targeted Therapies of Aggressive Thyroid Cancer. Front Endocrinol (Lausanne) (2015) 0.85
Advances in thyroid cancer treatment: latest evidence and clinical potential. Ther Adv Med Oncol (2015) 0.84
Identification of reproducible gene expression signatures in lung adenocarcinoma. BMC Bioinformatics (2013) 0.84
Evolving molecularly targeted therapies for advanced-stage thyroid cancers. Nat Rev Clin Oncol (2016) 0.84
New molecular targeted therapy and redifferentiation therapy for radioiodine-refractory advanced papillary thyroid carcinoma: literature review. J Thyroid Res (2012) 0.84
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res (2015) 0.83
Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions. Drugs (2015) 0.83
A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat Rev Endocrinol (2016) 0.83
Update: the status of clinical trials with kinase inhibitors in thyroid cancer. J Clin Endocrinol Metab (2014) 0.82
Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials. Onco Targets Ther (2014) 0.81
Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib. Biologics (2014) 0.81
QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer (2014) 0.80
Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer. Ther Adv Med Oncol (2014) 0.80
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol (2016) 0.78
Treating advanced radioresistant differentiated thyroid cancer. Lancet Oncol (2012) 0.78
Personalization of targeted therapy in advanced thyroid cancer. Curr Genomics (2014) 0.77
Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives. Drug Des Devel Ther (2016) 0.77
New insight into the treatment of advanced differentiated thyroid cancer. J Thyroid Res (2012) 0.77
First do no harm: counting the cost of chasing drug efficacy. Lancet Oncol (2012) 0.77
Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer. Oncotarget (2017) 0.76
Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment - initial experience. Sci Rep (2016) 0.75
Individualized multimodal treatment strategy for anaplastic thyroid carcinoma-Case report of long-term remission and review of literature. Int J Surg Case Rep (2016) 0.75
Selective use of vandetanib in the treatment of thyroid cancer. Drug Des Devel Ther (2015) 0.75
Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis. Onco Targets Ther (2015) 0.75
A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemother Pharmacol (2014) 0.75
Development of Photoonycholysis with Vandetanib Therapy. Skin Appendage Disord (2016) 0.75
Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas. Oncologist (2015) 0.75
A systematic review and meta-analysis of the risk of diarrhea associated with vandetanib treatment in carcinoma patients. Onco Targets Ther (2016) 0.75
Hürthle cell carcinoma: current perspectives. Onco Targets Ther (2016) 0.75
Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials. Oncotarget (2017) 0.75
Thyroid gland: vandetanib for thyroid cancer. Nat Rev Endocrinol (2012) 0.75
Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications. J Clin Med Res (2016) 0.75
Expression of glutamine metabolism-related proteins in thyroid cancer. Oncotarget (2016) 0.75
First-Line Use of Vemurafenib to Enable Thyroidectomy and Radioactive Iodine Ablation for BRAF-Positive Metastatic Papillary Thyroid Carcinoma: A Case Report. J Investig Med High Impact Case Rep (2015) 0.75
New agent to treat advanced or metastasized thyroid cancer, its efficacy, safety, and mechanism. Thorac Cancer (2015) 0.75
Treatment of distant metastases from follicular cell-derived thyroid cancer. F1000Prime Rep (2015) 0.75
Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials. Onco Targets Ther (2016) 0.75
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer. Onco Targets Ther (2016) 0.75
Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis. Int J Clin Oncol (2017) 0.75
Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. Cancer (2017) 0.75
Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma. Oncotarget (2017) 0.75
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 7.65
Bioelectrical impedance analysis--part I: review of principles and methods. Clin Nutr (2004) 7.24
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med (2007) 7.05
Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med (2014) 5.25
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol (2004) 5.12
Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med (2008) 4.39
Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med (2012) 3.86
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol (2007) 3.51
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist (2007) 3.42
Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol (2013) 3.37
Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol (2004) 3.28
The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol (2007) 3.20
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med (2011) 2.86
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol (2009) 2.77
Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet (2003) 2.54
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res (2011) 2.52
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol (2010) 2.34
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol (2011) 2.32
Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol (2005) 2.05
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol (2010) 2.03
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol (2009) 1.99
Transconvolution and the virtual positron emission tomograph--a new method for cross calibration in quantitative PET∕CT imaging. Med Phys (2013) 1.98
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol (2013) 1.79
FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck (2002) 1.66
Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist (2007) 1.61
Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res (2006) 1.58
High-intensity focused ultrasound ablation of thyroid nodules: first human feasibility study. Thyroid (2011) 1.58
Prospective evaluation of thyroid imaging reporting and data system on 4550 nodules with and without elastography. Eur J Endocrinol (2013) 1.53
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer (2011) 1.51
Cryptogenic late-onset epileptic spasms: an overlooked syndrome of early childhood? Epilepsia (2006) 1.43
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. BMC Cancer (2013) 1.43
Will the dark sky over advanced renal cell carcinoma soon become brighter? Eur J Cancer (2005) 1.43
Sleep disturbances associated with gastro-oesophageal reflux disease: prevalence and impact of treatment in French primary care patients. Dig Liver Dis (2011) 1.42
Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist (2008) 1.41
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol (2006) 1.40
Seizures and epilepsy in hypoglycaemia caused by inborn errors of metabolism. Dev Med Child Neurol (2014) 1.39
The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J Nucl Med (2005) 1.35
Reoperative surgery for thyroid disease. Langenbecks Arch Surg (2007) 1.34
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat (2014) 1.32
GPR56-related bilateral frontoparietal polymicrogyria: further evidence for an overlap with the cobblestone complex. Brain (2010) 1.30
Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer (2012) 1.28
Mutational, functional, and expression studies of the TCF4 gene in Pitt-Hopkins syndrome. Hum Mutat (2009) 1.28
177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy. Cancer (2010) 1.27
Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol (2007) 1.27
Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab (2010) 1.26
Is plasma 25(OH) D related to adipokines, inflammatory cytokines and insulin resistance in both a healthy and morbidly obese population? Endocrine (2010) 1.24
Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck (2006) 1.23
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging (2011) 1.13
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst (2009) 1.11
Evaluation of bone mineral density loss in morbidly obese women after gastric bypass: 3-year follow-up. Obes Surg (2011) 1.10
New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Crit Rev Oncol Hematol (2008) 1.08
A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin Cancer Res (2011) 1.08
Interleukin-6 and melanoma. Melanoma Res (2012) 1.07
Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients. Clin Cancer Res (2004) 1.06
Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. J Clin Endocrinol Metab (2004) 1.05
Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. Cancer Chemother Pharmacol (2008) 1.05
Salvage laryngectomy and pharyngocutaneous fistulae after primary radiotherapy for head and neck cancer: a national survey from DAHANCA. Head Neck (2003) 1.04
Duration of symptoms: impact on outcome of radiotherapy in glottic cancer patients. Int J Radiat Oncol Biol Phys (2005) 1.04
90Y Bremsstrahlung imaging for absorbed-dose assessment in high-dose radioimmunotherapy. J Nucl Med (2010) 1.03
Surgical resection and radiotherapy for primary retroperitoneal soft tissue sarcoma. Radiother Oncol (2002) 1.03
Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol (2003) 1.02
Change in tumor-absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients. Clin Cancer Res (2003) 1.01
Papillary thyroid microcarcinoma in Denmark 1996-2008: a national study of epidemiology and clinical significance. Thyroid (2013) 1.00
Thyroid hemiagenesis is a rare variant of thyroid dysgenesis with a familial component but without Pax8 mutations in a cohort of 22 cases. Pediatr Res (2005) 1.00
Prophylactic lymph node dissection in papillary thyroid carcinoma: is there a place for lateral neck dissection? World J Surg (2013) 1.00
Activation of a residual cortical network during painful stimulation in long-term postanoxic vegetative state: a 15O-H2O PET study. J Neurol Sci (2003) 0.99
Novel treatment strategies for soft tissue sarcoma. Crit Rev Oncol Hematol (2006) 0.98
Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma. Eur J Endocrinol (2012) 0.97
Molecular targeted therapies in breast cancer: where are we now? Int J Biochem Cell Biol (2007) 0.96
Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm). Crit Rev Oncol Hematol (2006) 0.96
Hypopharyngeal cancer: results of treatment based on radiation therapy and salvage surgery. Laryngoscope (2002) 0.95
PET-CT-guided interventions in the management of FDG-positive lesions in patients suffering from solid malignancies: initial experiences. Eur Radiol (2009) 0.95
Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy. J Clin Endocrinol Metab (2010) 0.95
Removal of hydrogen sulfide by immobilized Thiobacillus thioparus in a biotrickling filter packed with polyurethane foam. Bioresour Technol (2009) 0.94
Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res (2005) 0.94
Ultrasound, elastography, and fluorodeoxyglucose positron emission tomography/computed tomography imaging in Riedel's thyroiditis: report of two cases. Thyroid (2011) 0.94
The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev Oncol Hematol (2008) 0.94
A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma. Cancer Biother Radiopharm (2005) 0.94
Anticancer drug development: moving away from the old habits. Curr Opin Oncol (2014) 0.93
Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients. Melanoma Res (2009) 0.93
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer (2013) 0.92
PET/CT-guided biopsies of metabolically active bone lesions: applications and clinical impact. Eur J Nucl Med Mol Imaging (2010) 0.92
Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives. Crit Rev Oncol Hematol (2011) 0.92
Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. J Clin Oncol (2013) 0.92
The value of frozen section analysis of the sentinel lymph node in clinically N0 squamous cell carcinoma of the oral cavity and oropharynx. Otolaryngol Head Neck Surg (2005) 0.91
Evaluation of bone disease in morbidly obese women after gastric bypass and risk factors implicated in bone loss. Obes Surg (2009) 0.90
Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice? Crit Rev Oncol Hematol (2010) 0.90
Papillary thyroid carcinoma in Denmark 1996-2008: an investigation of changes in incidence. Cancer Epidemiol (2012) 0.90
The Danish national guidelines for treatment of oral squamous cell carcinoma. Acta Oncol (2006) 0.89
Molecular-targeted therapies: lessons from years of clinical development. Cancer Treat Rev (2007) 0.89
Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. Melanoma Res (2012) 0.89
Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial. J Clin Endocrinol Metab (2007) 0.89
Molecular biology in medical oncology: diagnosis, prognosis, and precision medicine. Discov Med (2014) 0.89
Cancer of the larynx--treatment results after primary radiotherapy with salvage surgery in a series of 1005 patients. Acta Oncol (2002) 0.89
Spectrum of epilepsy in terminal 1p36 deletion syndrome. Epilepsia (2007) 0.89
Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study. Breast Cancer Res Treat (2007) 0.89